Key result
Omics profiling identifies novel prognostic biomarkers and core pathogenic cascades across cardiac arrest and PCAS.
Why the study?
Post-cardiac arrest syndrome (PCAS) involves complex pathological mechanisms and heterogeneous prognoses, yet investigations applying multi-omics integration and molecular subtyping to disentangle its molecular pathophysiology remain scarce in cardiac arrest (CA) research.
Systematic Review
This systematic review of 39 studies demonstrates that while single-omics approaches reveal key pathogenic pathways and exploratory biomarkers in post-cardiac arrest syndrome, multi-omics integration and molecular subtyping require prospective multicenter validation before clinical implementation.
Answers are grounded in this paper and cite their sources.
Warrants prospective validation before prognostic use in cardiac arrest; extends pathway insights but leaves molecular subtyping open.
Post-cardiac arrest syndrome (PCAS) involves complex pathological mechanisms and heterogeneous patient prognoses. Although multi-omics integration and molecular subtyping hold great promise to disentangle molecular pathophysiology and advance precision care, such investigations remain scarce in cardiac arrest (CA) research. This systematic review summarizes CA research covering genomics, transcriptomics, proteomics, metabolomics, epigenomics, multi-omics, and molecular subtyping. Original studies published up to June 10, 2026, were retrieved from PubMed, Web of Science, and Cochrane Library. Thirty-nine eligible articles were retained after screening against predefined inclusion and exclusion criteria. Most included studies adopted single-omics approaches. Omics platforms identify novel prognostic biomarkers for CA and reveal core PCAS pathogenic cascades, including mitochondrial dysfunction, dysregulated immune-inflammatory responses, oxidative stress injury, and perturbed metabolic cascades. Preliminary transcriptomic and metabolomic subtyping attempts can stratify CA patient subgroups but require further external validation, laying an incomplete molecular foundation for personalized treatment. Current single-omics evidence yields exploratory molecular clues for CA risk screening, PCAS prognostic prediction, and mechanistic research, whereas multi-omics integration and molecular subtyping represent emerging frontiers. Clinical implementation of personalized omics-guided therapy still awaits large multicenter prospective verification.
No takes yet. Share an insight, caveat, or question.
Shan et al. (2026) conducted a systematic review in Cardiac arrest and post-cardiac arrest syndrome (PCAS). Single-omics, multi-omics integration, and molecular subtyping was evaluated on Prognostic biomarkers, pathogenic cascades, and patient subgroup stratification in cardiac arrest and PCAS. Omics platforms across 39 studies identified novel cardiac arrest prognostic biomarkers and core PCAS pathogenic cascades, though molecular subtyping requires external validation.
Synapse has enriched 10 related papers. Consider them for comparative context: